Relationship between the inclusion/exclusion criteria and sample size in randomized controlled trials for SARS-CoV-2 entry inhibitors

DOI10.1016/J.JTBI.2022.111403MaRDI QIDQ2684584zbMATH OpenOpenAlexFDO

Authors Daiki Tatematsu, Marwa Akao, Hyeongki Park, Shingo Iwami, Keisuke Ejima, Shoya Iwanami

Publication date 16 February 2023

Published in Journal of Theoretical Biology (Search for Journal in Brave)

Copyright license Creative Commons Attribution 4.0 International

Full work available at URL https://doi.org/10.1016/j.jtbi.2022.111403

zbMATH Keywords

clinical trialCOVID-19SARS-CoV-2virus dynamics

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Epidemiology (92D30)

Recommendations

• Improving precision and power in randomized trials for COVID‐19 treatments using covariate adjustment, for binary, ordinal, and time‐to‐event outcomes
• Simplified within-host and dose-response models of SARS-CoV-2
• Modeling the viral dynamics of SARS-CoV-2 infection
• Design of viral dynamic studies for efficiently assessing potency of anti-HIV therapies in AIDS clinical trials
• Time optimal control studies on COVID-19 incorporating adverse events of the antiviral drugs

This page was built for publication: Relationship between the inclusion/exclusion criteria and sample size in randomized controlled trials for SARS-CoV-2 entry inhibitors

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2684584)